Choreo LLC Takes Position in Celcuity, Inc. $CELC

Choreo LLC purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 5,028 shares of the company’s stock, valued at approximately $248,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CELC. Soleus Capital Management L.P. lifted its stake in shares of Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after acquiring an additional 437,696 shares in the last quarter. Vanguard Group Inc. raised its stake in Celcuity by 23.5% during the third quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock worth $101,717,000 after acquiring an additional 391,262 shares during the period. Eventide Asset Management LLC lifted its holdings in shares of Celcuity by 9.8% in the 2nd quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock worth $18,549,000 after purchasing an additional 123,774 shares during the last quarter. Saturn V Capital Management LP lifted its stake in Celcuity by 8.4% in the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after buying an additional 91,843 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Celcuity by 27.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock valued at $10,263,000 after purchasing an additional 166,324 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 20,000 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the transaction, the director owned 90,000 shares of the company’s stock, valued at approximately $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 15.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CELC. Jefferies Financial Group boosted their price target on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus raised their target price on shares of Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. HC Wainwright reiterated a “neutral” rating and issued a $94.00 price target (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Finally, Wolfe Research began coverage on Celcuity in a research note on Tuesday, November 18th. They set an “outperform” rating and a $110.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.25.

Celcuity Trading Down 0.1%

Celcuity stock opened at $115.16 on Monday. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32. The firm has a market capitalization of $5.33 billion, a PE ratio of -31.38 and a beta of 0.38. The business’s 50-day simple moving average is $107.40 and its 200-day simple moving average is $85.10. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.